Clinical Trials Browser

Phase 2 × Hormone-sensitive Metastatic Breast Cancer × Goserelin × Clear all

NCT01205685 2012-09-11

Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-Sensitive Metastatic Breast Cancer

Phase 2 Terminated

11 enrolled 9 charts

Hormone-sensitive Metastatic Breast Cancer